N1-(4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenyl)-1-benzenesulfonamide | 262432-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: N1-(4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenyl)-1-benzenesulfonamide
• 英文别名: N-(4-(4-Amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenyl)benzenesulfonamide；N-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]benzenesulfonamide
• CAS: 262432-51-9
• 化学式: C₂₃H₂₂ClN₅O₂S
• 分子量: 467.979
• InChiKey: SKKDNFOQMBGWSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS
  申请人：——

  公开号：US20030187001A1

  公开（公告）日：2003-10-02

  Chemical compounds having structural formula I 1 and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperpro;iferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

  具有结构式I1的化合物及其生理上可接受的盐是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞高增殖是因素的疾病状态。这些化合物可用于治疗癌症、高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• Method of treating transplant rejection
  申请人：Waegell Wendy

  公开号：US20050008640A1

  公开（公告）日：2005-01-13

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.

  本发明涉及一种治疗移植排斥的方法，包括向患者施用一种药物组合物，该药物组合物包括lck抑制剂和钙调蛋白酶抑制剂或免疫抑制剂。
• Three hybrid assay system
  申请人：GPC Biotech AG

  公开号：EP1975620A2

  公开（公告）日：2008-10-01

  The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hypbrid ligand compounds.

  本发明提供了用于分离用户指定配体的配体结合多肽的组合物和方法，以及使用改良的低杂合配体化合物分离用户指定目标多肽的小分子配体的组合物和方法。
• TPL-2/COT KINASE AND METHODS OF USE
  申请人：BASF AKTIENGESELLCHAFT

  公开号：US20020099169A1

  公开（公告）日：2002-07-25

  It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF&kgr;B, and thus as a modulator of inflammatory responses in which p105 is involved, and as a target for the development of compounds capable of influencing NF&kgr;B activation.

  研究表明，TPL-2 负责 p105 的磷酸化和由此产生的蛋白水解，从而导致 p50 Rel 转位至细胞核。因此，本发明提供的 TPL-2 是 NF&kgr;B 活化的特异性调节剂，因而是 p105 参与的炎症反应的调节剂，也是开发能够影响 NF&kgr;B 活化的化合物的靶标。
• TPL-2/COT kinase and methods of use
  申请人：——

  公开号：US20030219427A1

  公开（公告）日：2003-11-27

  It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF&kgr;B, and thus as a modulator of inflammatory responses in which p1O5 is involved, and as a target for the development of compounds capable of influencing NF&kgr;B activation.

  研究表明，TPL-2 负责 p105 的磷酸化及其蛋白水解，从而导致 p50 Rel 转位至细胞核。因此，本发明提供的 TPL-2 是 NF&kgr;B 活化的特异性调节剂，因而是 p1O5 参与的炎症反应的调节剂，也是开发能够影响 NF&kgr;B 活化的化合物的靶标。